Related Experiment Video
Updated: Mar 2, 2026
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
Supporting Molecular Tumor Boards in Molecular-Guided Decision-Making - The Current Status of Five German University
Marc Hinderer1, Melanie Boerries2, Florian Haller3
1Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
Background:
German university hospitals have started to establish molecular tumor boards in order to enable physicians to make molecular-guided decisions.
Objective:
Our aim was to describe the organizational structure and procedures which are currently supporting the molecular tumor boards of five German university hospitals.
Methods:
We conducted semi-structured interviews with experts of five university hospitals between December 2016 and February 2017.
Results:
We observed heterogeneity in both the organization of genetic testing and the management of the molecular tumor boards among the five hospitals. They used free-text documents in most of their support procedures rather than machine-readable documents.
Conclusion:
There are three potentialities to support the process from genetic testing to reporting within the molecular tumor boards: (i) standardized pipeline to integrate automated variant calling and annotation; (ii) tools supporting the experts in creating their reports and presentations and (iii) implementing pharmacogenomic CDSS into clinical routine.
